All-oral Hep C race heats up as AbbVie receives "breakthrough" status

Share this article:

AbbVie joined BMS today in gaining Breakthrough Therapy designation for an investigational Hep C treatment. The three drug combo of ABT-450/r (protease inhibitor and ritonavir), ABT-267 (an NS5A inhibitor) and ABT-333 (a non-nucleoside polymerase inhibitor) treats patients with genotype 1 of the chronic disease.

FDA's Breakthrough Therapy nod follows a promising Phase II clinical trial, named ‘Aviator'. In that trial, the three-drug combo saw 99% of patients hit the key benchmark of sustained viral response after 12 weeks of therapy. The combo will now move to Phase III trials.

John Leonard, SVP and Chief Scientific Officer, AbbVie, said in a release: "AbbVie is pleased that the FDA has granted Breakthrough Therapy designation to our 3-DAA combination with and without ribavirin. We feel it reflects the potential of this regimen to be important in the treatment of HCV."

Five days ago, Gilead released data from its Phase II "Lonestar" study, in which the company tested a combination of sofosbuvir, which has been submitted for FDA approval, and ledipasvir. The Foster-City, California based drugmaker said the virus was undetectable in 19 out of 20 subjects after only eight weeks.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...